2023 POSTER PRESENTATIONS COMING IN MARCH
P01: Above and Beyond: Measuring Lipophilicity of Large Molecules, Presented by Andrew C., Analiza, Inc.
P02: ASGPR-Targeting Chimeras (ATACs): A New Class of Degraders for Targeting Extracellular Proteins, Presented by Srinivasa K., Avilar Therapeutics
P03: Deconvolution of Structure-Activity Relationships of Peptide Inhibitors of the KEAP1/Nrf2 Protein-Protein Interaction Using Machine Learning, Presented by Samantha M., Boston University
P04: Identification of Selective Covalent Small Molecule Inhibitors of ZAP70, Presented by Ping C., BridGene Biosciences
P05: IMTAC™ - A Next Generation Chemoproteomic Platform to Discover Small Molecule Therapies for Hard-to-Drug Targets, Presented by Ping C., BridGene Biosciences
P06: Increasing DNA Encoded Library Screening Resolution Using HT-SPR, Presented by Rebecca R., Carterra
P07: Structural and Mutational Investigation of Human Hematopoietic Prostaglandin D2 Synthase and Inhibitors, Presented by Kendall M., Cayman Chemical Company, Inc.
P08: A Next Generation Fluorinated Fragment Library for 19F-NMR Ligand-Based Screening Incorporating the Latest Trends in Fragment Library Design, Presented by Chris H., Charles River Laboratories
P09: Towards Designing PROTACs by Coarse-Grained Modeling, Presented by Paulo Cesar T., CNRS and Universite de Lyon
P10: Molecular Interaction Analysis by Grating-Coupled Interferometry (GCI), Presented by Tatiana T., Creoptix AG
P11: Sensor Chip NA for High-Performance Biacore SPR Analysis, Presented by Cynthia s., Cytiva
P12: Analysis of Small Molecule Interactions on Nucleic Acid Secondary Structure: A Single Molecule Approach, Presented by Jimmy O., Depixus
P13: Ligand Identification from Natural Product-Inspired Collections Using AS-MS, Presented by Jean-Yves O., Edelris SAS
P14: Simplifying Degrader Discovery by Screening Across E3 Ligase Families, Presented by Jean B., Eurofins Discovery
P15: High Throughput Screening Cascade to Generate Highly Selective Hits for PIM3 Kinase, Presented by Poonam K., Eurofins Discovery
P16: Detect Conformational Change of Large Protein Induced by Small Molecules Using SPR, Presented by Qingliang S., Ferring Pharmaceuticals, Inc.
P17: Characterization of Molecular Glues – An Automated In-Solution Platform, Presented by Mays H., Fida Biosystems ApS
P18: Fully Automated Characterization of Ternary Complex Formation Using Flow Induced Dispersion Analysis, Presented by Mays H., Fida Biosystems ApS
P19: CryoDiscovery™: A Machine Learning Platform for Automated Cryo-EM Class Selection in Structure-Based Drug Discovery, Presented by Kennedy B., Health Technology Innovations, Inc.
P20: F2X-Universal Library and F2X-Entry Screen - Structurally Diverse Fragment Libraries Yield Unprecedented Hit Rates in Crystallographic Screening, Presented by Tatjana B., Helmholtz-Zentrum Berlin
P21: Routes for Synthesis of Metabolites of Ruxolitinib and Epacadostat, Presented by Liam E., Hypha Discovery Ltd.
P22: J2H-2002, an Oral, Selective, and Potent Protein Degrader for the Treatment of NSCLC with Osimertinib-Resistant EGFR C797S Mutations, Presented by Sooji Y., J2H Biotech
P23: Building a Diverse and Experimentally Curated Fluorine Fragment Library, Presented by Andrew L., Key Organics Ltd.
P24: Fragment Libraries for FBDD, Presented by Vasily P., Life Chemicals, Inc.
P25: Harnessing the Biophysical Fragment Screening Sweet Spot to Discover New Chemotypes for BRPF1 Inhibition, Presented by Verna F., Malvern Panalytical
P26: Structural Insights into the Inhibition of the SARS-CoV-2 Main Protease (Mpro) by Small Molecules, Presented by Haydar B., National Institutes of Health, National Cancer Institute
P27: Proton Transport Mechanism in Liquid Imidazole: A First Principle Molecular Dynamics Study, Presented by Zhuoran L., New York University
P28: Case Study: Streamlining Hit-to-Lead Discovery with Deep Learning Platform Cerella™, Presented by Scott L., Optibrium Ltd.
P29: Reimagining Compound Idea Generation with Dynamic Learning to Generate Better Compounds, Presented by Kylee M., Optibrium Ltd.
P30: A Novel AI-Assisted Design Approach to Discover Selective Inhibitor for FLT3 (D835Y) in Acute Myeloid Leukemia, Presented by SooMin C., PharmCADD
P31: Lumit™ Protein Interaction Immunoassays Using Protein Tags and Biotinylated Small Molecules, Presented by Steven E., Promega Corporation
P32: Unlocking Targeted Protein Degradation, Presented by Steven E., Promega Corporation
P33: Broad Spectrum Cellular Kinase Selectivity Profiling in Live Cells with NanoBRET™ Technology, Presented by Kara M., Promega Corporation
P34: NanoBRET as a Live Cell Method to Assess PROTAC Affinity and Intracellular Availability for E3 Ligases, Presented by Kara M., Promega Corporation
P35: BRET Probes for Profiling Reversible Engagement of RAS in Live Cells, Presented by Joel W., Promega Corporation
P36: True High-Throughput Analysis of Transporter Activity Screens – Using Echo® MS System, Presented by Loren O., SCIEX
P37: Metabolite Profiling and ID of Cyclic Peptides Using Automated Software Processing and High-Resolution Mass Spectrometry, Presented by Bahar R., SCIEX
P38: University of California Drug Discovery Consortium: Linking Academia with Industry, Presented by Jordan K., University of California Drug Discovery Consortium
P39: LYsine COvalent Degraders (LYCODE): Exploring E3-Covalent Ligands for Targeted Protein Degradation, Presented by Giulia A., University of California, Riverside
P40: NMR-Guided Design of Potent and Selective EphA4 Agonistic Ligands, Presented by Carlo B., University of California, Riverside
P41: Bi-Functional Ligands for Targeted Degradation of Surface Receptors, Presented by Anne Marie P., University of California, Riverside
P42: Discovery of Novel cPLA2 Inhibitors Using VSYNTHES2.0, Presented by Anastasiia S., University of Southern California
P44: Developing Selective Inhibitors for HDAC3 via CAP Group Structure-Activity Relationship, Presented by Diaa A., University of Toronto, Mississauga
P45: Chemoproteomic Characterization of a Novel Halobenzene Warhead and Its Applications in Drug Discovery, Presented by Ayah A., University of Toronto, Mississauga
P46: First-in-Class DNAJ-PRKACA Inhibitor for the Treatment of Fibrolamellar Hepatocellular Carcinoma, Presented by Rebecca A., University of Toronto, Mississauga
P47: Structural and Biophysical Implications of STAT5B SH2 Domain Mutation in Blood Cancers, Presented by Qirat A., University of Toronto, Mississauga
P48: A Comprehensive 19F NMR-Based Fragment Screening Platform for GPCR Ligand Discovery, Presented by Geordon F., University of Toronto, Mississauga
P49: Exploring Strategies for Selective Degradation of Histone Deacetylase 6 (HDAC6) in Multiple Myeloma, Presented by Harsimran G., University of Toronto, Mississauga
P50: Development of Covalent Microtubule Inhibitors as Treatments for Hematological Malignancies, Presented by Christina G., University of Toronto, Mississauga
P51: Capture-Covalent Immobilization for Single Cycle Kinetic Analysis of Conformationally-Constrained HDAC8 Inhibitors, Presented by Johan I., University of Toronto, Mississauga
P52: Bifunctional Molecules Beyond PROTACs: Preliminary Data Involving Induced Phosphorylation of HDAC6, Presented by Erica Q., University of Toronto, Mississauga
P53: JAK-STAT Core Cancer Interactome, Presented by Tudor R., University of Toronto, Mississauga
P54: Decorating Bacteria with Self-Assembled Synthetic Receptors, Presented by Pragati P., Weizmann Institute Of Science
P55: Case Studies of Combining DNA-Encoded Library and Machine Learning to Maximize the Opportunities of Hit Discovery, Presented by Jason D., WuXi AppTec
P56: DNA-Encoded Chemical Library Technology and Its Application Towards TAM Kinases, Presented by Paige D., X-Chem, Inc.
P57: Building the Next Generation AI-Driven Drug Design Engine-Self-Evolving, Learning from Scratch De Novo Drug Design, Presented by Xing C., YDS Pharmatech
P58: Discovery of Macrocyclic Peptides as Antagonists and PPI Inhibitors Directly from Functional Screens, Presented by Rumit M., Zonsen Peplib Biotech
P59: Novel HTS-Compatible Peptide Discovery Platform for the Screening of Functionally Active Peptides, Presented by Sally W., Zonsen Peplib Biotech
P60: Multimodal Transformer-based Model for Buchwald-Hartwig and Suzuki-Miyaura Reaction Yield Prediction, Presented by Shimaa B., Integrant, Inc.
P61: Protein-Based Virtual Screening Tools for RNA-Ligand Docking: Can We Trust Them?, Presented by Christian K., Johannes Gutenberg University
P62: Development and Applications of Covalent CBX Chromodomain Probes, Presented by Sijie W., Purdue University
P63: A Small Molecule Drug Design for Targeting WNK1 in Triple Negative Breast Cancer, Presented by Ashari K., UT Southwestern Medical Center
P64: Targeting ML-IAP with Lys-Covalent Antagonists: Design, Synthesis, and Cellular Activity, Presented by Parima U., University of California, Riverside